Related Experiment Video
Updated: May 29, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
Brain Structures and Cognitive Decline: Moderation Analysis of the PACt-MD Randomized Clinical Trial of Brain
Natalie C W Ho1, Peter Zhukovsky2, Tarek K Rajji3
1Institute of Medical Science (NCWH, TKR, YC, CEF, AJF, NH, LM, BGP, ANV, BHM), University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute (NCWH, PZ, CRB, HB, YC, AL, BGP, CM, ANV, BHM), Centre for Addiction and Mental Health, Toronto, ON, Canada.
Objective:
To identify which patients with remitted major depressive disorder (rMDD) or mild cognitive impairment (MCI) benefit from cognitive remediation (CR) plus transcranial direct current stimulation (tDCS).
Design:
We conducted a moderator analysis to examine the effects of baseline brain magnetic resonance imaging (MRI) measures on the impact of CR + tDCS on cognitive decline in Prevention of Alzheimer's dementia with CR plus tDCS in MCI and Depression (PACt-MD), a double-masked randomized two-arm controlled trial with assessments at baseline, two months, and yearly for three to seven years.
Setting:
Five academic hospitals in Toronto, Canada.
Participants:
A total of 246 participants with rMDD, MCI, or both, with an analyzable baseline MRI.
Intervention:
CR + tDCS or sham CR + sham tDCS.
Measurements:
Overall cortical thickness, overall fractional anisotropy, and cortical thickness in an a-priori composite region of interest (ROI); changes in global cognition, executive function, or verbal memory.
Results:
Overall cortical thickness moderated decline in global cognition (Χ² = 10.43, df = 3, p = 0.015); ROI cortical thickness moderated treatment-related changes in global cognition (Χ² = 29.05, df = 3, p <0.001), executive function (Χ² = 11.57, df = 3, p = 0.009), and verbal memory (Χ² = 16.08, df = 3, p = 0.001).
Conclusion:
Future work needs to confirm that cortical thickness can be used to select adults at risk for dementia who are the most likely to benefit from CR + tDCS. CLINCIALTRIALS.
Gov Identifier:
NCT02386670.
Related Concept Videos
Cognitive Development During Adulthood
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
